A new series of imidazolones, particularly compound 21 (SR 47436), demonstrated potent AT1 receptor antagonism in preclinical models, leading to clinical trials for hypertension.
Answers are grounded in this paper and cite their sources.
Supports advancement of imidazolone AT1 antagonists to clinical testing; leaves open confirmation of efficacy and safety in humans.
Starting from the structure of the novel nonpeptide AT1 receptor antagonist DuP 753 (losartan), a new series of potent antagonists was designed. In these compounds the central imidazole nucleus was replaced by the dihydroimidazol-4-one structure. The most active compounds had a spirocyclopentane or a spirocyclohexane ring in position 5. Like the imidazole series, the best substituents were the linear butyl chain in position 1 and the [2'-(tetrazol-5-yl)biphenylyl]methyl group in position 3. Antagonistic activity was assessed by the ability of the compounds to competitively inhibit [125I]AII binding to the AT1 subtype receptor and to antagonize AII-induced contractions in rabbit aorta rings. The most active compounds had IC50 values in the nanomolar range. In conscious rats, compounds 4 and 21 antagonized the AII pressor response when administered orally. Compound 21 (SR 47436) was the most active; it was recently shown to also be active in cynomolgus monkeys both intravenously and orally. This molecule is now undergoing clinical trials for the treatment of hypertension.
No takes yet. Share an insight, caveat, or question.
BERNHART et al. (1993) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: